Compound for treating viral infection and preparation method and application of compound

A compound and solvate technology, applied in the field of methods and intermediates, to prepare the compound, can solve the problems of limited curative effect and high cost

Pending Publication Date: 2021-08-06
HC SYNTHETIC PHARMA CO LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The monoclonal antibody palivizumab is available for immunoprophylaxis, but its use is limited to high-risk infants, eg, premature infants or those with congenital heart or lung disease, and is often cost prohibitive for general use
In addition, the nucleoside analog ribavirin has been approved as the only antiviral agent for the treatment of HRSV infection with limited efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound for treating viral infection and preparation method and application of compound
  • Compound for treating viral infection and preparation method and application of compound
  • Compound for treating viral infection and preparation method and application of compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0132] Example 1: Ethyl (2S)-2-(chloro(phenoxy)phosphorylamino)propionate (chloride A1)

[0133]

[0134] Ethylalaninate hydrochloride (2.54g, 16.5mmol) was dissolved in anhydrous dichloromethane (30ml) and the mixture was cooled to 0°C with stirring under N2 (g). Phenyl dichlorophosphate (2.23 mL, 25 mmol) was added, followed by the dropwise addition of triethylamine over 10 min. The reaction mixture was then slowly warmed to RT and stirred for 12 h. Anhydrous acetic anhydride (150 mL) was added, and the mixture was stirred for 30 min. The solid formed was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was chromatographed on silica gel eluting with 0-50% EtOAc in hexanes to provide chloride Al (1.86 g, 39%).

[0135] 1 H NMR (300 MHz, CDC13) δ 7.39-7.27 (m, 5H), 4.27 (m, 3H), 1.52 (m, 3H), 1.32 (m, 3H).

[0136] 31 P NMR (121.4MHz, CDCl 3 )δ8.2,7.8.

Embodiment 2

[0137] Example 2: 9-ethylbutyl (2S)-2-(chloro(phenoxy)phosphorylamino)propionate (chloride B1)

[0138]

[0139] 2-Ethylbutylalanine chlorophosphoramidate B1 was prepared using the same procedure as chloride A1 except that 2-ethylbutylalanine was used instead of ethylalanine. The crude material was used in the next reaction. Treatment with methanol or ethanol forms a surrogate product with the desired LCMS signal.

Embodiment 3

[0140] Example 3: Isopropyl (2S)-2-(chloro(phenoxy)phosphorylamino)propionate (chloride C1)

[0141]

[0142] Isopropylalanine chlorophosphoramidate C1 was prepared using the same procedure as chloride A1 except that isopropylalanine was used instead of ethylalanine. The crude material was used in the next reaction. Treatment with methanol or ethanol forms a surrogate product with the desired LCMS signal.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a preparation for treating viral infection and pneumovirus subfamily viral infection, a method, a compound as shown in a formula (I) and a method and intermediate for synthesis of the compound as shown in the formula (I).

Description

technical field [0001] Provided herein are compounds, methods and pharmaceutical formulations useful in the treatment of Pneumovlrlnae viral infections, including, in particular, respiratory viral infections, as well as processes and intermediates useful in the preparation of the compounds. Background technique [0002] Pneumovirinae viruses are negative-sense, single-stranded RNA viruses that are responsible for many prevalent human and animal diseases. The pneumovirinae subfamily of viruses is part of the Paramyxoviridae family and includes the human respiratory syncytial virus (HRSV). Almost all children experience HRSV infection by their second birthday. HRSV is a leading cause of lower respiratory tract infections in infants and children, with 0.5% to 2% of those infected requiring hospitalization. Older adults and adults with chronic heart disease, lung disease, or those who are immunosuppressed are also at high risk for developing severe HRSV disease. There is curr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07H19/16C07H19/04C07H1/00C07H19/20C07D487/04C07F9/6561A61P31/14A61P11/00A61K31/675A61K31/706A61K31/7064A61K31/7076A61K31/53A61K31/519
CPCA61P11/00A61P31/14C07D487/04C07F9/6561C07H1/00C07H19/04C07H19/16C07H19/20
Inventor 杨成张起愿陆华龙
Owner HC SYNTHETIC PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap